Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Calcium and Magnesium for Ixabepilone-Induced Neuropathy
NCT00998738Phase 3Terminated
- Sponsor
- Mayo Clinic
- Start
- Nov 2009
- Primary completion
- Jul 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of calcium gluconate and magnesium sulfate in chemotherapy-induced peripheral neuropathy (CIPN) (2 arms), sponsored by Mayo Clinic. Primary endpoint: Chemotherapy-induced Peripheral Neuropathy Sensory Subscale of EORTC QLQ-CIPN20 at 18 weeks. Started Nov 2009; status: terminated.
02
Drugs
calcium gluconatemagnesium sulfate
03
Conditions
chemotherapy-induced peripheral neuropathy (CIPN)
Beyond the preview
Go deeper on NCT00998738.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00998738.